D
Axsome Therapeutics, Inc.
AXSM
$121.91
$0.260.21%
D
Sell
3/14/2023Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the solvency index, total return index and growth index. Debt to equity increased from 0.6 to 0.86, the quick ratio declined from 4.11 to 2.47, and EBIT declined 31.24% from -$42.45M to -$55.72M.
Axsome Therapeutics, Inc. (AXSM) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the solvency index, total return index and growth index. Debt to equity increased from 0.6 to 0.86, the quick ratio declined from 4.11 to 2.47, and EBIT declined 31.24% from -$42.45M to -$55.72M.
D
Sell
2/23/2023Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
D
Sell
2/8/2023Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to D- from D on 02/08/2023.
Axsome Therapeutics, Inc. (AXSM) was downgraded to D- from D on 02/08/2023.
D
Sell
8/19/2022Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from D- on 8/19/2022 due to an increase in the total return index, growth index and volatility index.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from D- on 8/19/2022 due to an increase in the total return index, growth index and volatility index.
D
Sell
5/31/2022Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E+ on 5/31/2022 due to an increase in the valuation index.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E+ on 5/31/2022 due to an increase in the valuation index.
E
Sell
5/13/2022Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/4/2022Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index and solvency index.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index and solvency index.
E
Sell
5/1/2022Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D on 05/01/2022.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/21/2022Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index and valuation index.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index and valuation index.
E
Sell
4/20/2022Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index, valuation index and solvency index. Debt to equity increased from 1.17 to 3.18, and the quick ratio declined from 4.64 to 3.75.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index, valuation index and solvency index. Debt to equity increased from 1.17 to 3.18, and the quick ratio declined from 4.64 to 3.75.
D
Sell
11/10/2021Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from D- on 11/10/2021.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from D- on 11/10/2021.
D
Sell
11/8/2021Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index, solvency index and efficiency index. Debt to equity increased from 0.52 to 0.7, the quick ratio declined from 7.59 to 6.18, and total capital declined 17.03% from $146.42M to $121.49M.
Axsome Therapeutics, Inc. (AXSM) was downgraded to D- from D on 11/8/2021 due to a significant decline in the total return index, solvency index and efficiency index. Debt to equity increased from 0.52 to 0.7, the quick ratio declined from 7.59 to 6.18, and total capital declined 17.03% from $146.42M to $121.49M.
D
Sell
3/16/2020Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from D- on 3/16/2020 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 2.36 to 8.98, and debt to equity declined from 2.9 to 0.11.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D from D- on 3/16/2020 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 2.36 to 8.98, and debt to equity declined from 2.9 to 0.11.
D
Sell
10/8/2018Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E+ on 10/8/2018 due to an increase in the total return index and volatility index.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E+ on 10/8/2018 due to an increase in the total return index and volatility index.
E
Sell
8/14/2018Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D- on 8/14/2018 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.1884 to -$0.3211, debt to equity increased from 0.73 to 1.21, and the quick ratio declined from 2.83 to 2.14.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D- on 8/14/2018 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.1884 to -$0.3211, debt to equity increased from 0.73 to 1.21, and the quick ratio declined from 2.83 to 2.14.
D
Sell
5/21/2018Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E+ on 5/21/2018 due to a large increase in the growth index and total return index. Earnings per share increased from -$0.3067 to -$0.1884.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E+ on 5/21/2018 due to a large increase in the growth index and total return index. Earnings per share increased from -$0.3067 to -$0.1884.
E
Sell
4/25/2018Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D- on 4/25/2018 due to a decline in the total return index and volatility index.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D- on 4/25/2018 due to a decline in the total return index and volatility index.
D
Sell
8/11/2017Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E+ on 8/11/2017 due to an increase in the total return index, solvency index and volatility index. Debt to equity declined from 0.45 to 0.34, and the quick ratio increased from 5.11 to 5.39.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E+ on 8/11/2017 due to an increase in the total return index, solvency index and volatility index. Debt to equity declined from 0.45 to 0.34, and the quick ratio increased from 5.11 to 5.39.
E
Sell
3/8/2017Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D- on 3/8/2017 due to a decline in the solvency index, efficiency index and valuation index. Net income declined 1.87% from -$7.19M to -$7.33M.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D- on 3/8/2017 due to a decline in the solvency index, efficiency index and valuation index. Net income declined 1.87% from -$7.19M to -$7.33M.
D
Sell
1/20/2017Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E+ on 1/20/2017 due to an increase in the valuation index.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E+ on 1/20/2017 due to an increase in the valuation index.
E
Sell
1/4/2017Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D- on 1/4/2017 due to a decline in the total return index, valuation index and volatility index.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E+ from D- on 1/4/2017 due to a decline in the total return index, valuation index and volatility index.
D
Sell
8/1/2016Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E on 08/01/2016.
Axsome Therapeutics, Inc. (AXSM) was upgraded to D- from E on 08/01/2016.
E
Sell
7/27/2016Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to E from E+ on 7/27/2016 due to a decline in the volatility index, total return index and valuation index.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E from E+ on 7/27/2016 due to a decline in the volatility index, total return index and valuation index.
E
Sell
7/12/2016Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to E+ from E on 7/12/2016 due to an increase in the volatility index.
Axsome Therapeutics, Inc. (AXSM) was upgraded to E+ from E on 7/12/2016 due to an increase in the volatility index.
E
Sell
6/17/2016Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to E from E+ on 6/17/2016 due to a large decline in the total return index and volatility index.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E from E+ on 6/17/2016 due to a large decline in the total return index and volatility index.
E
Sell
6/2/2016Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to E+ from E on 6/2/2016 due to a noticeable increase in the total return index and valuation index.
Axsome Therapeutics, Inc. (AXSM) was upgraded to E+ from E on 6/2/2016 due to a noticeable increase in the total return index and valuation index.
E
Sell
5/12/2016Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to E from E- on 5/12/2016 due to an increase in the total return index and efficiency index.
Axsome Therapeutics, Inc. (AXSM) was upgraded to E from E- on 5/12/2016 due to an increase in the total return index and efficiency index.
E
Sell
4/27/2016Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to E- from E on 4/27/2016 due to a decline in the total return index, valuation index and volatility index.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E- from E on 4/27/2016 due to a decline in the total return index, valuation index and volatility index.
E
Sell
3/28/2016Upgraded
Axsome Therapeutics, Inc. (AXSM) was upgraded to E from E- on 3/28/2016 due to a noticeable increase in the solvency index, volatility index and growth index. The quick ratio increased from 1.94 to 18.25, and earnings per share increased from -$0.412 to -$0.1188.
Axsome Therapeutics, Inc. (AXSM) was upgraded to E from E- on 3/28/2016 due to a noticeable increase in the solvency index, volatility index and growth index. The quick ratio increased from 1.94 to 18.25, and earnings per share increased from -$0.412 to -$0.1188.
E
Sell
3/11/2016Downgrade
Axsome Therapeutics, Inc. (AXSM) was downgraded to E- from E on 3/11/2016 due to a noticeable decline in the volatility index.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E- from E on 3/11/2016 due to a noticeable decline in the volatility index.
E
Sell
2/17/2016None
Axsome Therapeutics, Inc. (AXSM) was downgraded to E from U on 02/17/2016.
Axsome Therapeutics, Inc. (AXSM) was downgraded to E from U on 02/17/2016.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
